ViiV Healthcare’s investigational broadly neutralising antibody – N6LS – successfully maintains viral suppression in long-acting treatment of HIV

FHS
March 13, 2025
10:18 am

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Daiichi Sankyo-AstraZeneca’s ENHERTU gets FDA priority review

Share this article A decision on the approval of ENHERTU to treat unresectable or metastatic HER2-positive solid tumours is expected on 30 May 2024. Credit:

January 29, 2024

Revitalist Announces Strategic Partnership with Sama Therapeutics to Advance Digital Human AI Agents for Precision Mental Health | Psychedelic Invest

Vancouver, British Columbia–(Newsfile Corp. – September 9, 2024) – Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO), a leader in comprehensive mental

September 12, 2024

Study reveals a paradigm shift in the understanding of T-lineage acute lymphoblastic leukemia

Researchers at Children’s Hospital of Philadelphia (CHOP), St. Jude Children’s Research Hospital (St. Jude) and the Children’s Oncology Group (COG) today announced a significant paradigm

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.